The idea of combining lipid-lowering therapeutics with anti-inflammatory drugs is getting increasingly recognized (Ridker, 2020), and targeting GsdmD in combination of LDL lowering therapies such as statins or PCSK9 antibody may serve as potential therapeutic to treat atherosclerosis and CVD. Here, PCSK9 is linked to atherosclerosis.